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Abstract In this population-based study, we determined
the frequency and clinical characteristics of leptomeningeal
disease (LMD) developing in the context of oligodendrog-
lial tumors (oligodendrogliomas and oligoastrocytomas).
LMD occurred in only 3.9% (8/204) of oligodendroglial
tumors and in patients with more recurrences [mean 2.88 vs.
1.27 in LMD and non-LMD, respectively (p = 0.001)]. In
contrast to LMD from systemic solid tumors, the median
survivalfollowingthediagnosisofLMDinoligodendroglial
tumors was surprisingly long at 22 months (95% CI
11–33 months). Treatment with oral chemotherapy seemed
as effective as more aggressive treatments (e.g. repeat RT or
intrathecal chemotherapy) in these patients.
Keywords Oligodendroglial tumors  Leptomeningeal
spread
Introduction
Oligodendroglial tumors (oligodendrogliomas and mixed
oligoastrocytomas) represent 5–20% of gliomas [1, 2]. In
oligodendroglial tumors, co-deletion of chromosomes 1p
and 19q (likely a manifestation of a recurring unbalanced
1q/19p translocation) is associated with better overall
prognosis [3–5] and response to treatment [6–8]. We
recently encountered a series of patients with the unusual
complication of leptomeningeal disease (LMD) from oli-
godendroglial tumors which had several unusual features
(e.g. survival with LMD of up to 3.6 years in one patient)
[9]. We performed this study to determine how commonly
this occurred at the population level and to identify clinical
features that might predict the occurrence of LMD.
Patients and methods
Ethical approval was received from the Conjoint Health
Research Ethics Board of the University of Calgary to
review charts for every patient diagnosed with an oligo-
dendroglial tumor (oligodendrogliomas and mixed oligo-
astrocytomas WHO grades II and III) diagnosed in
Southern Alberta (population 1.8 million) between 1 July
1991 and 31 Aug 2009. Patients were identiﬁed through the
Alberta Cancer Registry and their individual records were
reviewed.
Of the 208 identiﬁed patients, four were excluded
because they were lost to follow-up without data available.
In our institution 1p/19q status was evaluated in the
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or ﬂuorescent in situ hybridization (FISH) techniques.
The criteria for the diagnosis of leptomeningeal disease
(LMD) were any two or more of the following [9]: (1)
neurological symptoms or signs consistent with LMD, (2)
MRI changes consistent with LMD (i.e., leptomeningeal,
subependymal, or subarachnoid spread), or (3) a cytologi-
cal diagnosis of LMD on examination of cerebrospinal
ﬂuid (CSF).
Statistics
Results were analyzed with SPSS Version 16.0 for
Microsoft Windows and were two-tailed. For continuous
variables, Spearman’s rank correlation test was used to
identify associations. For categorical variables, Chi-square
or Fisher’s exact tests were used. When comparing the
means of continuous variables between groups, an unpaired
two group t-test was used.
Progression-free survival (PFS) was deﬁned as the
interval between initial diagnosis and evidence of recur-
rence/progression, death, or lost to follow up. Overall
survival (OS) was calculated from date of initial diagnosis
to death or lost to follow-up. Time to ﬁrst onset of LMD
was calculated from initial tumor diagnosis.
The Kaplan–Meier method was used to estimate distri-
butions forPFS andOS.Thelog-ranktestwasusedtoassess
differences between these distributions with respect to the
occurrence of clinical variables. Cox multivariate analysis
(forward stepwise Wald) was done to assess their indepen-
dent predictive value. All tests were two-tailed and p-values
less than 0.05 were considered statistically signiﬁcant.
Results
Population-based analysis of oligodendroglial tumors
and risk of LMD
From July 1991 to August 2009, 208 patients in Southern
Alberta were diagnosed with oligodendroglial grade II and
III tumors; 204 were included in this analysis. This corre-
sponds to an incidence of 1/100,000/year. Their charac-
teristics are summarized in Table 1. For the entire group,
Table 1 Clinical characteristics of patients with oligodendroglial tumors that developed leptomeningeal disease compared with 196 that did not
Total Population
(n = 204)
LMD
(n = 8)
a
No LMD
(n = 196)
b
Signiﬁcance
(p)
a vs.
b
Mean age in years (range) 42 (18–78) 40 (28–50) 42 (18–78) 0.636
Median KPS (range) 85 (50–100) 85 (70–90) 90 (50–100) 0.477
Debulking (%) 173 (85) 7 (87.5) 166 (85) 0.828
Pathology at diagnosis (%) 0.079
• Oligo. Gr. II 62 (30.5) 1 (12.5) 61 (31.1)
• Oligo. Gr. III 49 (24) 5 (62.5) 44 (22.4)
• Mixed OA Gr. II 52 (25.5) 1 (12.5) 51 (26)
• Mixed OA Gr. III 41 (20) 1 (12.5) 40 (20.4)
1p/19q 0.127
• Not tested (%) 43 (21) 1/7 (14) 42 (21)
• Codeleted
c (% of tested) 93/161 (58) 6/7 (86) 87/154 (56.4)
Initial treatment (%) 0.785
• Observation 96 (47) 5 (62.5) 91 (46)
• RT alone 35 (17) 1 (12.5) 34 (17.3)
• ChT alone 18 (9) 1 (12.5) 17 (9)
• SeqRTChT 26 (13) 0 26 (13.3)
• ConcRTChT 29 (14) 1 (12.5) 28 (14.3)
Mean number of recurrences 1.35 2.88 1.27 0.001
PFS (months) (mean; 95% CI) 67 (59–75) 47 (22–72) 68 (59–77) 0.176
OS (months) (mean; 95% CI) 130 (118–142) 107 (82–132) 133 (120–146) 0.063
LMD leptomeningeal disease, Oligo oligodendroglioma, OA oligoastrocytoma, RT radiotherapy, ChT chemotherapy, SeqRTChT sequential RT
followed by ChT, ConcRTChT concurrent RT and ChT, PFS progression free survival, OS overall Survival
a Patients with leptomeningeal disease
b Patients without leptomeningeal disease
c Includes patients with only 1p loss
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123mean age at diagnosis was 42 years (range 18–78) and 120
patients (59%) were male. None of the 204 patients had
oligodendroglial tumors originated from the posterior fossa.
Four patients had bifrontal tumors and the rest were dis-
tributed homogeneously in the hemispheres with 108/200
(54%) in the left hemisphere. 137/204 (67%) of the patients
had tumors involving the frontal lobes. Biomarker data was
available on 161 patients (79%); 93 (58%) were co-deleted
for 1p and 19q.
With respect to initial treatment, 85/114 (75%) patients
with low grade tumors were observed (i.e., received no
tumor treatment beyond surgery) while 78/90 (87%) with
anaplastic tumors received immediate postoperative treat-
ment that consisted of radiotherapy (RT) alone (14%),
chemotherapy (ChT) alone (24%), RT followed by ChT
(32%) or concurrent RT and ChT (30%).
We analyzed clinical factors associated with OS and
found that published prognostic factors were relevant in
our population. Univariate analysis for OS showed that
females lived longer (Log Rank test; p = 0.036). Among
grade III tumors, patients with pure oligodendrogliomas
lived a mean of 124 months compared to 84 months for
those with mixed tumors (p\0.0001). Patients with WHO
grade II histology lived longer than those with anaplastic
(grade III) tumors (p\0.0001) and co-deletion of 1p/19q
was associated with better overall survival (p = 0.004).
Extent of initial resection did not impact OS (even when
controlling for pathology, WHO grade, or genetic subtype).
Tumors recurred in 122 patients and 73 had further surgery.
Surgery at ﬁrst recurrence was associated with longer OS
(mean OS of 140 vs. 97 months; p = 0.001).
Comparison of clinical and pathological characteristics
in patients with LMD
Only 3.9% (8 of 204) of patients with oligodendroglial
tumors developed LMD during the 18 year study period
(Table 1). The only factor statistically associated with
LMD was the number of tumor recurrences that were
higher in the LMD group (mean of 2.88 recurrences) as
compared to the no-LMD group (1.27 recurrences;
p = 0.001). There was no signiﬁcant difference in patients
with or without LMD in terms of age, KPS, surgical
resection, pathology [pure vs. mixed; p = 0.47) or low
grade vs. high grade (p = 0.073)], co-deletion of 1p/19q
(p = 0.127), or initial postoperative treatment (p = 0.785).
Outcomes in patients with LMD
The mean time from the initial diagnosis of a brain tumor
until the diagnosis of LMD was 77 months (95% CI
51–102 months). Surprisingly, in contrast to LMD from
systemic solid tumors or GBM which have a universally
poor prognosis, the progression-free and overall survivals
were not statistically different between patients with and
without LMD (Table 1) although there was a trend for both
to be shorter in patients with LMD (Fig. 1). The mean
survival following the diagnosis of LMD mean was
22 months (95% CI 11–33 months) but this varied con-
siderably from 1.8 to 42 months (Fig. 2).
Subanalysis in patients with 1p/19q co-deletion
Considering the subjectivity and evolution of pathologic
criteria for the diagnosis of pure and mixed oligoden-
droglial tumors, we thought that genetic subtyping would
provide a more objective classiﬁcation. We included a total
of 93 patients that had 1p/19q co-deletion or 1p loss. In this
subgroup again the number of recurrences was associated
with development of LMD with a mean of 1.1 and 2.8
recurrences for patients without and with LMD, respec-
tively (p = 0.004). 0.2% (1/53) and 12.5% (5/40) of
patients with low and high grade tumors developed LMD,
Fig. 1 Progression free survival (a) and overall survival (b)o f
patients with oligodendroglial tumors with and without LMD
measured from the initial pathological diagnosis
J Neurooncol (2011) 104:811–815 813
123respectively (p = 0.04). In this subgroup the median sur-
vival was 107 months (95% CI 101–113 months) for
patients that developed LMD. This was signiﬁcantly
shorter than 177 months (95% CI 155–199 months) for
patients without LMD (p = 0.033).
Discussion
To our knowledge, this is the ﬁrst population-based study of
the rare complication of LMD in oligodendroglial tumors.
Other population-based studies of oligodendroglioma [10,
11]havenotreportedthiscomplication.WefoundthatLMD
occurred in 3.9% of patients with oligodendroglial tumors,
usually later in the natural history of the disease. The only
clinical factor statistically associated with its development
was the number of tumor recurrences. This could also be a
surrogate for multiple surgeries but incomplete information
on treatment of recurrences precludes a deﬁnitive conclu-
sion. There was a trend for LMD to develop in patients with
anaplastic tumors with 1p19q co-deletion and in those who
were observed initially rather than treated with chemother-
apy or radiotherapy immediately after diagnosis. In patients
harboring 1p/19q codeletion, the diagnoses of LMD implied
shorter OS. Survival following the diagnosis of LMD varied
widely but on average was almost 2 years. This contrasts
with rapidlyfatal LMD inthosewith GBM orsystemicsolid
tumors [12, 13].
Our subgroup analysis of anaplastic oligodendrogliomas
found a trend for patients who did not receive postoperative
treatment with radio- or chemotherapy to develop LMD.
We are uncertain about optimal treatment in this setting.
Our patients tolerated various therapies, including intra-
thecal thiotepa, but we found no complete or partial
responses. We now avoid potentially toxic therapies in
these patients with longer survivals and use oral temozol-
omide, a DNA methylating agent that penetrates the CNS
and is well tolerated.
Our study has limitations which may have falsely raised
or lowered the true incidence of LMD. A higher rate might
reﬂect our longstanding interest in this disease or tendency
to investigate with neuro-imaging and lumbar puncture
seemingly minor symptoms or signs. Conversely, the
incidence might be spuriously low because craniospinal
axis MRI/routine CSF examination were not routinely
performed in all oligodendroglial tumor patients. We are
also limited in the conclusions we can draw because of the
very small number of patients. Therefore only the strongest
risks of LMD were identiﬁed and trends we observed (e.g.
the association of 1p and 19q co-deletion) may be con-
ﬁrmed in larger studies.
Finally, this study is also limited to classical clinical and
pathological variables gleaned from cancer registry data
and chart review. Central pathology review was not per-
formed for our study, and the classiﬁcation of the tumors
might have varied between pathologists. Furthermore,
diagnostic practices may have changed over the course of
the study period that could impact the classiﬁcation of
tumors as pure oligodendroglioma or mixed oligodendro-
gliomas. We were unable to evaluate the association of
ventricle opening during surgery to the development of
LMD. Aside from some data on 1p and 19q status, our
study does not further interrogate genomic/molecular fac-
tors that could either inﬂuence the classiﬁcation of oligo-
dendroglial tumors or contribute to the risk of LMD. We
are now using genomic technologies in archival formalin-
ﬁxed parafﬁn-embedded tumor samples in patients from
this study to determine if we can identify genomic signa-
tures associated with this rare complication.
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